LOUISVILLE, Ky.--(BUSINESS WIRE)--PharMerica Corporation (the “Corporation” or the “Company”) (NYSE: PMC), a national provider of institutional, specialty home infusion, hospital and oncology pharmacy services, today reported its financial results for the fourth quarter and full year ended December 31, 2016.
| 4Q’16 Results |
Comparison to |
Comparison to 3Q’16 |
|||||||||||||||||||
| Revenue | $534.4 million | Increase of 2.7% | Increase of 4.3% | ||||||||||||||||||
| Gross profit | $83.7 million | Decrease of 3.5% | Increase of 6.6% | ||||||||||||||||||
|
Selling, general and |
$54.8 million | Decrease of 1.1% | Increase of 3.2% | ||||||||||||||||||
| Net income | $7.7 million | Decrease of 61.9% | Increase of 5.5% | ||||||||||||||||||
|
Diluted earnings per |
$0.25 | Decrease of 62.1% | Increase of 8.7% | ||||||||||||||||||
| Adjusted EBITDA | $35.6 million | Increase of 2.6% | Increase of 13.0% | ||||||||||||||||||
|
Adjusted diluted earnings |
$0.58 | Increase of 3.6% | Increase of 31.8% | ||||||||||||||||||
|
Generic drug dispensing rate |
85.3% |
Decrease of 100 basis points |
Decrease of 30 basis points |
||||||||||||||||||
